Real-World Impact on Heart Failure Mortality and

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Real-World Impact on Heart Failure Mortality and Readmissions of Individualized Care Guided by Blood Volume Analysis: New Data Presented at the American College of Cardiology Congress

NEW YORK, NY--(Marketwired - Apr 6, 2016) - Daxor Corporation ( NYSE MKT : DXR ), an investment company with medical instrumentation and biotechnology operations, announces the first interventional outcomes data to be presented in heart failure patients receiving individualized care guided by direct blood volume analysis (BVA). The data were presented at the American College of Cardiology congress by John E. Strobeck, MD, PhD during a moderated poster presentation session, "Hemodynamics in Heart Failure: What's New?", on Saturday, April 2 (abstract 1160M-01). Co-authoring the analysis was Wayne L. Miller, MD, PhD, of the Mayo Clinic.

Dr Joseph Feldschuh, Chief Scientific Officer for Daxor, noted, "The improvement in heart failure mortality and readmissions that Dr Strobeck has achieved compared to benchmarks are provocative and very encouraging. It is my hope that the individualized care BVA makes possible will enable meaningful progress to be made in our approach to managing this high-needs patient population."

Dr Strobeck reported the results of a retrospective analysis of mortality and readmissions outcomes in a mixed community cohort of 250 patients hospitalized for heart failure over the course of four years for whom at least 1 year of follow-up data were available or death was recorded within 1 year. Patients received at least one BVA test at or near admission with follow-up as needed. BVA results were integrated into each patient's decongestion strategy. Outcomes for this cohort were statistically compared to hospital (30-day mortality and readmissions rates) or national (365-day mortality rate) Medicare benchmark outcomes.

For this real-world mixed cohort of 250 heart failure patients receiving individualized care guided by BVA, the 30-day all-cause mortality rate was 1.2%, which is significantly lower than the institutional Medicare benchmark rate of 10.7% ( P < 0.001), implying an 84% relative reduction in the risk of 30-day readmissions compared with conventionally managed patients. This difference in mortality was maintained to one year, with a 365-day mortality rate of 3.6% vs the national Medicare benchmark rate of 22.0% ( P < 0.001).

The 30-day readmissions rate in this cohort was 11.6%, which is significantly lower than the institutional Medicare benchmark rate of 24.2% ( P < 0.001), implying a 52% relative reduction in the risk of 30-day readmissions compared with conventionally managed patients. Since 2013, Medicare has been financially penalizing hospitals with above-average 30-day readmissions rates for heart failure patients. This result has important implications not only for improving the treatment of heart failure but also for reducing hospital financial penalties.

Dr Strobeck stated, "Directly measuring intravascular blood volume makes it possible to individualize the decongestion strategy according to the confirmed and quantified need of each patient. Based on the outcomes observed in this cohort, this may represent an important difference from the conventional approach. Effectively identifying and managing the anemia also seems to meaningfully impact outcomes."

Volume overload is a hallmark of heart failure, and the accurate measurement and management of congestion is a core concern for physicians in this setting. Clinical signs and symptoms alone are well understood to be inadequately sensitive and specific in the evaluation of volume status. Indirect metrics such as hemodynamic pressures, although informative in other respects, have demonstrated poor correlation with measured total blood volume. Alternative direct technologies utilizing dyes and fluorescing markers have repeatedly failed to deliver accurate results. Only BVA enables clinicians to measure a patient's blood volume directly and with 98% accuracy. Additionally, BVA is the only metric for quantifying RBC volume status to deliver consistent accuracy regardless of plasma expansion or depletion.

Although many observational studies with BVA have been performed in heart failure, this independent single-center retrospective cohort study represents the first time interventional outcomes utilizing individualized management strategy guided by BVA have been reported in the heart failure setting.

Stated Michael Feldschuh, acting President and CEO: "This exciting interventional study reinforces the importance of the ACC guidelines' emphasis on the importance of achieving euvolemia (normal blood volume) in treating hospitalized heart failure patients. The results confirm the existing body of observational evidence suggesting that normal blood volume at discharge is predictive of better outcomes in heart failure patients. Dr Strobeck's outcomes suggest the potential for BVA-guided care to reduce mortality and readmissions to a meaningful degree, with concomitant resource utilization benefits for hospitals and healthcare systems, through the use of a simple, quick, and noninvasive test."

Daxor Corporation manufactures and markets the BVA-100 Blood Volume Analyzer, which is used in conjunction with Volumex, Daxor's single-use diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website at www.Daxor.com .

Daxor Contact Information: Michael Feldschuh Acting President and CEO 646-321-8305 Email Contact Lisa Quartley Senior Vice President, Marketing and Commercial Development 212-330-8518 Email Contact or Richard Dunn Director of Operations 212-330-8502 Email Contact

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Qonto's Banking License Raises the Stakes in Europe

Updated Category News Views 46

A regulatory stamp can look dull on paper, yet this one changes the machinery underneath Qonto. The Paris-based finance platform has received a Credit Institution license from France's ACPR and the European Central Bank, giving it a route to offer broader lending and savings products directly to small and midsize businesses across Europe. That is a serious corporate...

Continue Reading
LifeVac's 7,000 Reported Saves Deserve Careful Context

Updated Category News Views 138

Veggie straws are supposed to be harmless until they are not. LifeVac says a 19-month-old girl in South Dakota became unable to breathe on November 14 after eating the snack, with a sticky piece creating a complete airway obstruction. Her father retrieved the family's LifeVac, used the pediatric mask while she was on her back, and the company says one application...

Continue Reading
Aurora Innovation Faces Legal Probe After Stock Plunge

Updated Category News Views 136

Aurora's Troubles Draw Legal Scrutiny Looks like Aurora Innovation’s in the hot seat again, and not in a good way. When you see Kessler Topaz Meltzer & Check, LLP throwing their name into the mix, you know it’s getting serious. This legal eagle firm is poking around, seeing if Aurora stepped over the line with investors after their latest stumble—a production delay...

Continue Reading
Navan’s Travel Survey Sells Friction as a Business Case

Updated Category News Views 154

A forgotten charger can turn a routine trip into a small mutiny. That is the useful little truth sitting underneath Navan’s new survey of 2,000 Americans who travel for leisure or business. The company is poking at the annoyances people carry from the bedroom packing pile to the jet bridge: forgotten items, rushed airport arrivals, pre-flight drinks, chatty strangers,...

Continue Reading
Bank of America AML Claims Put Controls Under Fire

Updated Category News Views 157

A $1.2 billion compliance bill has a way of making investors stop pretending controls are boring. Moore Law PLLC is urging Bank of America shareholders to contact the firm over allegations tied to the bank's anti-money-laundering and Bank Secrecy Act systems. The notice follows what it describes as landmark October 13, 2026 enforcement actions by the Treasury Department's...

Continue Reading
Animal Parasite Market Growth Has a Resistance Catch

Updated Category News Views 156

Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...

Continue Reading
Madrigal Pharmaceuticals Faces Legal Scrutiny Over Data

Updated Category News Views 152

Legal Storm Brews for Madrigal Pharmaceuticals Watch out, here comes another storm for Madrigal Pharmaceuticals, folks. This ain't no small drizzle either; it's a full-on legal monsoon, and it's soaked straight through the walls of their executive suite. We're talking a whistleblower sending alarm bells ringing about data fudging and some dodgy boardroom maneuvers—as if...

Continue Reading
Red Cat Stock Drama: Revenue Targets and Legal Waves

Updated Category News Views 123

Red Cat's Revenue Predictions Crash and Burn Sitting there on August 6, 2026, Red Cat Holdings had everyone believing they were on a fast track to hitting a hefty revenue target: $150–$180 million for FY2026. CEO Jeffrey Thompson didn't mince words, boasting confidence like a captain before a storm. Fast forward three months, and they're waving the white flag, tossing...

Continue Reading
FULC, DSGR and OPCH Deals Draw Fresh Shareholder Scrutiny

Updated Category News Views 85

Three proposed transactions have drawn the kind of legal glare that makes shareholders sit up and check the fine print twice. On November 18, 2026, Halper Sadeh LLC said it was investigating deals involving Fulcrum Therapeutics, Distribution Solutions Group, and Option Care Health for possible federal securities-law violations or fiduciary-duty breaches. That is not a...

Continue Reading
BNY's December Conference Slot Merits a Careful Listen

Updated Category News Views 118

A 10:40 a.m. conference appearance can look like wallpaper on a market calendar, but BNY's scheduled December 9 discussion deserves more attention than that. Robin Vince, the chief executive, is set to speak at the Goldman Sachs Financial Services Conference in New York, and the company has plainly warned that the conversation may include forward-looking statements and...

Continue Reading

Top 5 Most Recently Viewed Articles

Wicked Cutz, Cinnabon Team Up for Bacon Jerky Debut

Updated Category News Views 13

Ever thought you'd see the day when your protein snack could taste like a cinnamon roll? Well, folks, that day has arrived. Wicked Cutz, a force in the meat snack industry, and Cinnabon, the undisputed champs of cinnamon rolls, have rolled out a product that's bound to raise some eyebrows: bacon jerky with a sweet pastry twist. Why Bacon Jerky? You might be wondering, why...

Continue Reading
10 High-Yielding Small-Cap Stocks Under $15 in 2024

Updated Category Stocks Views 542

In the ever-evolving landscape of the stock market, small-cap stocks can be a gold mine for investors seeking high yields without breaking the bank. As we navigate through 2024, let's delve into a curated list of 10 small-cap stocks trading under $15 that offer attractive dividend yields. But remember, high yields can be as enticing as they are perilous, so tread with...

Continue Reading
Frazier Life Sciences Secures Over $630M for Growth Initiatives

Updated Category News Views 239

Frazier Life Sciences (FLS) raised over $630 million back in 2024, which got everyone buzzing on the trading floor. This wasn't just pocket change; it came from an oversubscribed fundraise that saw new and existing investors jumping on board like it was Black Friday. Talk about a cash infusion! The Public Fund has amassed around $1.7 billion since its launch three years...

Continue Reading
1847 Holdings LLC Achieves Milestone with $11.1M Offering

Updated Category News Views 112

1847 Holdings LLC Successfully Completes Public Offering 1847 Holdings LLC (NYSE American: EFSH), a company dedicated to investing in high-potential middle-market businesses, recently announced an exciting achievement. The firm has successfully closed its public offering, resulting in gross proceeds of $11.1 million. This accomplishment reflects the company's continued...

Continue Reading
Live Nation Entertainment's Stock Analysis Amid Sell-Off

Updated Category News Views 238

Understanding Live Nation Entertainment's Recent Stock Movements The trading landscape for Live Nation Entertainment, Inc. (LYV) has seen quieter activity following a significant sell-off of 6.5%. Investors and market analysts are closely observing whether this stock will continue its downward trajectory. Technical Analysis: Support and Resistance Levels Identifying Key...

Continue Reading